Rottenstein Law Group Notes With Approval Suggestion of FDA Advisory Panel That Fosamax Carry Label
The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, agrees with the recommendation of two FDA advisory panels that Fosamax and other bisphosphonates should carry label warnings advising those taking the drugs to speak with their prescribing physicians regularly to re-evaluate the risks and benefits of the medication. New York, NY (PRWEB) September 12, 2011 According to a Reuters article, two advisory panels of the U.S. Food and Drug Administration on Friday “declined to suggest how long women should take a class of drugs used by m
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 309
- Bankruptcy 44
- Business 134
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 608
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4